CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL.

Tokunaga E

Open source

DOI
10.21037/tbcr-25-28
Published
2026
Container
Translational breast cancer research : a journal focusing on translational research in breast cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/tbcr-25-28,
  title = {CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL.},
  author = {Tokunaga E},
  year = {2026},
  journal = {Translational breast cancer research : a journal focusing on translational research in breast cancer},
  doi = {10.21037/tbcr-25-28},
  url = {https://doi.org/10.21037/tbcr-25-28}
}

RIS

TY  - JOUR
TI  - CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL.
AU  - Tokunaga E
PY  - 2026
JO  - Translational breast cancer research : a journal focusing on translational research in breast cancer
DO  - 10.21037/tbcr-25-28
UR  - https://doi.org/10.21037/tbcr-25-28
ER  - 

APA

E, T. (2026). CDK4/6 inhibitors for premenopausal women with hormone receptor-positive/HER2-negative breast cancer; insight from Young-PEARL.. Translational breast cancer research : a journal focusing on translational research in breast cancer. https://doi.org/10.21037/tbcr-25-28

Source records